March 1, 2017 / 9:26 PM / 5 months ago

BRIEF-Fibrogen reports fiscal 2016 financial results

1 Min Read

March 2 (Reuters) - Fibrogen Inc

* Fibrogen reports fiscal 2016 financial results

* Sees to report pamrevlumab topline phase 2 ipf data, placebo-controlled and combination treatment sub-study results, in q3

* Fibrogen inc- on track to submit nda for roxadustat in u.s. In 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below